CONVERTIBLE NOTE DUE JANUARY 31, 2021Convertible Note • December 28th, 2020 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
THIS CONVERTIBLE NOTE is a duly authorized and validly issued Note of GT BIOPHARMA, INC., a Delaware corporation, (“Borrower”), having its principal place of business at 9350 Wilshire Blvd, Suite 203, Beverly Hills, CA 90212, due January 31, 2021 (the “Maturity Date”) (this note, the “Note”).
SETTLEMENT AGREEMENTSettlement Agreement • December 28th, 2020 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Settlement Agreement (the “Agreement”) is made and entered into by and among Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (“Alto B”), GT Biopharma Inc. (“GT Biopharma”), Anthony Cataldo (“Cataldo”) and Paul Kessler (“Kessler”). Alto B, GT Biopharma, Cataldo and Kessler are each referred to as a “Party” and, collectively, as “Parties.”
